Express Pharma
Home  »  Market  »  Healthcare industry records 103 deals worth $55.3 billion in December 2020

Healthcare industry records 103 deals worth $55.3 billion in December 2020

One big-ticket deal contributes 70.5 per cent of the total deal value in December 2020

0 290
Read Article

In December 2020, the healthcare industry reported 103 deals worth $55.3 billion as compared to the last 12-month average (December 2019 to November 2020) of 83 deals worth $13.5 billion.

AstraZeneca to acquire Alexion Pharmaceuticals, a biopharma company, for $39 billion or $175 per share was the big-ticket deal which contributed 70.5 per cent of the total deal value in December 2020. Other top deals during the period were EQT IX Fund to acquire Recipharm AB, a contract development and manufacturing organisation, for approximately $2.1 billion; Les Laboratoires Servier SAS to acquire commercial, clinical and research-stage oncology portfolio of Agios Pharmaceuticals, a biopharma company, for up to $2 billion and Gilead Sciences to acquire MYR GmbH for $1.7 billion.

Deal Date Acquirer (s) Target Deal Value
($ million)
12-Dec-20 AstraZeneca Plc (UK) Alexion Pharmaceuticals Inc (US) 39,000.0
14-Dec-20 EQT IX Fund (Sweden) Recipharm AB (Sweden) 2,116.8
21-Dec-20 Les Laboratoires Servier SAS (France) Oncology Business of Agios Pharma (US) 2,000.0
10-Dec-20 Gilead Sciences Inc (US) MYR GmbH (Germany) 1,755.0
10-Dec-20 Boehringer Ingelheim International GmbH (Germany) NBE-Therapeutics AG (Switzerland) 1,428.2

 

VC investments value decreased in December 2020

The healthcare industry reported 112 venture capital (VC) deals worth $3.8 billion in December 2020, compared to the last 12-month average (December 2019 to November 2020) of 121 deals worth $3 billion.

Tempus Labs, a technology company specialised in advancing precision medicine through the collection and analysis of molecular and clinical data, raising $200 million in series G-2 financing round to expand its operations and establish its work in other disease areas, including infectious diseases, depression, and cardiology; Nuance Biotech, raising $181 million in series D round of financing to support its ongoing research and development of its existing products and business development of potential new assets, and Cullinan Oncology, raising $131.2 million in series C round of financing are the major VC deals reported in December 2020.

Deal Date Acquirer (s) Target Deal Value ($ million)
10-Dec-20 Baillie Gifford & Co; Google LLC; Franklin Templeton Investments; Novo Holdings AS; T Rowe Price Associates Inc Tempus Labs Inc (US) 200.0
8-Dec-20 Matrix Partners China; RTW Investments LP; Beijing Konruns Pharmaceutical Co Ltd; C-Bridge Capital Partners LLC; HBM Healthcare Investments AG; GT Fund Nuance Biotech Inc (China) 181.0
15-Dec-20 Schooner Capital LLC; Orbimed Advisors LLC; Undisclosed Investor(s); F2 Ventures Limited; Nextech Invest Ltd; Venrock Healthcare Capital Partners LP; The Baupost Group  LLC; Foresite Capital Management LLC; Boxer Capital LLC; Eventide Asset Management, LLC; BVF Partners LP; MPM Capital Inc; Rock Springs Capital Management LP; Cowen Healthcare Investments; Logos Global Management LLC Cullinan Oncology LLC (US) 131.2
17-Dec-20 BlackRock Inc; EcoR1 Capital LLC; Alexandria Venture Investments; Redmile Group LLC; Cormorant Asset Management LLC; Casdin Capital LLC; Undisclosed Fund; Samsara BioCapital LLC; Janus Henderson Investors; ArrowMark Partners; Avidity Partners LLC; Ascendant BioCapital Neurogene Inc (US) 115.0
16-Dec-20 Undisclosed Investor(s) Neomorph Inc (US) 109.0

Source: GlobalData 

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Know Importance of using different levels of Controls
Register Now!
close-image